Semin Thromb Hemost 1997; 23(2): 189-196
DOI: 10.1055/s-2007-996090
Copyright © 1997 by Thieme Medical Publishers, Inc.

Anticoagulation in Patients with Heparin-Induced Thrombocytopenia Type II

Job Harenberg, Günter Huhle, Lukas Piazolo, Lianchun U. Wang, Dieter L. Heene
  • From the 1st Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
Further Information

Publication History

Publication Date:
08 February 2008 (online)

Abstract

Heparin-induced thrombocytopenia (HIT) together with simultaneously occurring thromboembolism is a serious complication of heparin treatment. At present an immunologic cause of this side effect of heparin is equivocally accepted. However, further anticoagulation of these patients is still debated. The present article summarizes the treatment of 20 patients with such complications. Two of these patients did not develop thrombocytopenia but presented cutaneous allergy or necrosis. All patients were treated either with intravenous heparinoid (Orgaran) or with low-molecular-weight heparin without/with simultaneous intravenous high-dose immunoglobulins or with intravenous r-hirudin. Based on these experiences the treatment of choice depends at present on the availability of the anticoagulants and on the local experience with the different anticoagulants. In the future r-hirudins and other nonheparin thrombin inhibitors may become the drugs of choice in this indication. Surgical intervention has to be considered additionally.